Fobrepodacin clinical trials
Also written SPR720.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses fobrepodacin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- SPR720
- 3
Studies by the year they started
4 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 2 |
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses fobrepodacin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacterium Avium Complex (MAC) Pulmonary DiseaseCompletedPhase 2Spero TherapeuticsNCT05496374Written as SPR720 500 mg
- A Study to Assess the Intrapulmonary Pharmacokinetics (PK) of SPR719 by Comparing the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations Following the Oral Administration of Multiple Doses of SPR720 in Healthy Volunteers.CompletedPhase 1Spero TherapeuticsNCT05955586Written as SPR720
- A Study to Evaluate the Effect of Co-administration on the Pharmacokinetics of SPR720, Azithromycin, and Ethambutol in Healthy ParticipantsCompletedPhase 1Spero TherapeuticsNCT05966688Written as SPR720
- Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary DiseaseTerminatedPhase 2Spero TherapeuticsNCT04553406Written as SPR720
Codes
What other systems call fobrepodacin · ClinicalTrials.gg INT000358
- MeSH (NLM) C000603606fobrepodacinOne source NLM
- UNII (FDA) 1NL76YUU6EFOBREPODACINConfirmed FDA, NLM
- NCI Thesaurus C184916FobrepodacinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000603606 | fobrepodacin | One source NLM |
| UNII (FDA) | 1NL76YUU6E | FOBREPODACIN | Confirmed FDA, NLM |
| NCI Thesaurus | C184916 | Fobrepodacin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.